{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pharmacogenomic+studies", "query": { "intervention": "pharmacogenomic studies" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 309, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pharmacogenomic+studies&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T20:35:12.504Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01071564", "title": "RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2009-11", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01071564" }, { "nct_id": "NCT01967576", "title": "Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "Axitinib (AG-013736)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 14, "start_date": "2013-10-19", "completion_date": "2020-12-01", "has_results": true, "last_update_posted_date": "2021-01-06", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967576" }, { "nct_id": "NCT03772535", "title": "Pharmacogenetics for Pain Management in Joint Replacement Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthroplasty Complications" ], "interventions": [ { "name": "Pharmacogenomics Testing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Anderson Orthopaedic Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-12-03", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-02-12", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 1, "location_summary": "Alexandria, Virginia", "locations": [ { "city": "Alexandria", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03772535" }, { "nct_id": "NCT01970501", "title": "Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Current or Recent History of Atrial Fibrillation" ], "interventions": [ { "name": "bucindolol hydrochloride", "type": "DRUG" }, { "name": "metoprolol succinate", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ARCA Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 267, "start_date": "2014-04", "completion_date": "2017-12-28", "has_results": true, "last_update_posted_date": "2022-09-26", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 48, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "East Palo Alto", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01970501" }, { "nct_id": "NCT03943927", "title": "Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Post-operative Atrial Fibrillation" ], "interventions": [ { "name": "Guided Metoprolol Management", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2021-03-05", "completion_date": "2022-11-20", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03943927" }, { "nct_id": "NCT01479842", "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "BTK inhibitor PCI-32765", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Kami Maddocks, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2014-03-26", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479842" }, { "nct_id": "NCT03370718", "title": "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Carcinoma in the Adrenal Cortex", "Stage III Adrenal Cortex Carcinoma AJCC v8", "Stage IV Adrenal Cortex Carcinoma AJCC v8", "Unresectable Adrenal Cortex Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-02-26", "completion_date": "2024-01-12", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370718" }, { "nct_id": "NCT05987956", "title": "Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "ALK-Positive Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "ALECENSA - alectinib hydrochloride capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "24 Years to 64 Years" }, "enrollment_count": 600, "start_date": "2026-03-18", "completion_date": "2026-12-28", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 2, "location_summary": "Doral, Florida • Rockville, Maryland", "locations": [ { "city": "Doral", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987956" }, { "nct_id": "NCT03674138", "title": "Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression", "Anxiety", "Generalized Anxiety Disorder", "Depressive Disorder", "Major Depressive Disorder", "Cancer" ], "interventions": [ { "name": "DNA-guided choice of therapy", "type": "DIAGNOSTIC_TEST" }, { "name": "Clinical management", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2018-09-12", "completion_date": "2024-10-27", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03674138" }, { "nct_id": "NCT05037305", "title": "VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pharmacogenomic Testing" ], "interventions": [ { "name": "Educational video", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 798, "start_date": "2022-06-30", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-04T20:35:12.504Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05037305" } ] }